详情页 - 云南省第一人民医院机构库

当前位置：首页 > 详情页

Could cytokine release syndrome induce acute myelofibrosis in CD19 chimeric antigen receptor T cells therapy?

59| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [a]Department of Hematology, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, China [b]Shenzhen Geno-Immune Medical Institute, Shenzhen, China [c]The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China [d]Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, Yunnan, China [e]Department of Hematology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China [f]Department of Clinical Laboratory, The First People’s Hospital of Yunnan Province, Kunming, Yunnan, China [g]Department of Pathology, The First People’s Hospital of Yunnan Province, Kunming, Yunnan, China [h]The Medical University of Dali, Dali, Yunnan, China [i]Cancer Biotherapy Center, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, China

出处：

DOI：

ISSN：

关键词： AMF B-ALL BMF CAR-T CRS

摘要：

CAR-T cells therapy can give rise to most common and concerning two side effects–cytokine release syndrome (CRS) and neurotoxicity. But in our CD19 CAR-T cells therapy clinical trial, we observed 1 out of 17 patients with B-cell acute lymphoblastic leukemia (B-ALL) developed acute myelofibrosis(AMF) after grade IV CRS post to the CD19 CAR-T cells therapy. This finding suggests that the CAR-T cells therapy may have rare and serious AMF, which we should pay important attention to. Trial registration:NCT02968472. Registered 18 November 2016–Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02968472. © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 4 区生物

小类 | 4 区生物工程与应用微生物

最新[2023]版：

大类 | 4 区生物学

小类 | 4 区生物工程与应用微生物

JCR分区：

出版当年[2019]版：

Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

最新[2023]版：

Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

影响因子： 4.2 最新[2023版] 4.2 最新五年平均 2.205 出版当年[2019版] 2.15 出版当年五年平均 1.544 出版前一年[2018版] 3.269 出版后一年[2020版]

第一作者：

第一作者机构： [a]Department of Hematology, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, China

通讯作者：

通讯机构： [i]Cancer Biotherapy Center, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, China [*1]Cancer Biotherapy Center, Kunming 650118, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Eradication of T-ALL cells by CD7 targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management. [2]Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma [3]CAR-T免疫疗法与非小细胞肺癌：瓶颈与曙光 [4]Therapeutic effects of chimeric antigen receptor T cells (CAR-T) on relapse/refractory diffuse large B-cell lymphoma (R/R DLBCL): a meta-analysis [5]CAR-T免疫治疗在血液肿瘤治疗中的研究现状和挑战 [6]A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia [7]Therapeutic effects of chimeric antigen receptor T cells (CAR-T) on relapse/refractory diffuse large B-cell lymphoma (R/R DLBCL): A meta-analysis [8]A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies [9]Fast-CAR-T细胞治疗难治复发CD19+ 急性淋巴细胞白血病 [10]crispr/cas9技术在car-t细胞治疗肿瘤中作用的研究进展